Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K reports the resolutions passed at the 145th Ordinary General Meeting of Shareholders held on June 29, 2021. The filing covers matters reported on and resolved regarding the 144th fiscal year (April 1, 2020 to March 31, 2021).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. It references the Consolidated Financial Statements for the 144th fiscal year as a matter reported on, but does not include the numerical data within this document.
Material Changes and Resolutions
- Dividends: The appropriation of surplus was approved, setting the year-end dividend at 90 yen (JPY90.00) per share.
- Board Elections: Twelve directors not on the Audit and Supervisory Committee were re-elected, including President Christophe Weber. One new director, Masami Iijima, was elected to the Audit and Supervisory Committee.
- Executive Compensation: Approval was granted to pay bonuses totaling up to 500 million yen to three specific directors (excluding overseas and external directors) in office at the end of the fiscal year.
- Articles of Incorporation: A partial amendment was approved to allow general meetings to be held without a specified venue in situations such as infectious disease spread or natural disasters.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the operational flexibility added to the Articles of Incorporation regarding meeting venues during emergencies.
Investor Verification Checklist
- Verify the full Consolidated Financial Statements for the 144th fiscal year to obtain revenue and profit figures not included in this summary.
- Confirm the exact number of shares outstanding to calculate the total dividend payout based on the 90 yen per share rate.
- Review the specific criteria for the 500 million yen director bonus allocation.
- Check subsequent filings for details on how the new "venue-less" meeting provision may be utilized.